Login / Signup

Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data.

Maria GontikaCharalampos SkarlisNikolaos MarkoglouMaria-Eleftheria EvangelopoulosGeorge VelonakisGeorge P ChrousosMarinos DalakasLeonidas StefanisMaria C Anagnostouli
Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021)
Our preliminary results support that response of POMS patients to fingolimod may be partially dependent on age and previous DMT, with younger and treatment-naïve patients presenting worse outcomes. The role of immunogenetics and immunophenotyping in personalized treatment warrants investigation in larger and more diverse populations.
Keyphrases